EL7.AI
StocksMediumUpdated×2•Originally published 28 July 2026•Updated 28 July 2026•
1 min read

IQVIA Raises Annual Profit Forecast as Shares Surge 11% on Strong Demand

Key Facts

1IQVIA reported Non-GAAP EPS of $3.15, beating analyst estimates by $0.12.
2IQVIA's revenue reached $4.37 billion, exceeding expectations by $70 million.
3Incyte also reported strong results with an EPS of $3.09 and revenue of $1.67 billion.

Reflecting the resilience of the healthcare services sector, IQVIA Holdings Inc. raised its annual profit forecast after reporting second-quarter results that surpassed Wall Street expectations. The company posted adjusted earnings per share of $3.15, beating estimates by $0.12, on total revenue of $4.37 billion. This upward revision highlights strong momentum and sustained demand for clinical research and healthcare data services.

This positive trajectory is underpinned by a substantial $24.4 billion backlog, providing high visibility for future revenue streams. Per market data, the broader sector remains robust, with peer Incyte reporting an EPS of $3.09 and revenue of $1.67 billion. According to analyst reports, IQVIA’s R&D solutions revenue grew by 8.8% year-over-year, validating the company's decision to lift its full-year guidance.

Shares of IQV surged 11% in pre-market trading, moving significantly higher from the July 27, 2026, closing price of $213.22. Investors will now focus on the company's execution of its backlog following the ECB's recent decision to hold interest rates at 2.4%. In the absence of immediate forward catalysts in the upcoming calendar, the stock's performance will likely depend on its ability to convert optimistic guidance into sustained bottom-line growth.

Latest Updates · 1

  1. Notable·

    Update: The company has further strengthened its growth outlook by entering a strategic clinical data-analytics partnership, prompting HSBC and Deutsche Bank to raise their price targets for the stock. Additionally, markets are looking ahead to an upcoming testimony by the company’s R&D leadership before the U.S. Congress, which may provide further insights into regulatory and sector-wide trends.